NMPA accepted the application for anti PD-1 monoclonal antibody penpulimab (官网)
HKEX Listing(Stock Code: 9926)
We established CTTQ-Akeso
We formed Sino Biopharm Collaboration to codevelop and co-commercialize penpulimab (官网)
We obtained the IND approval for a clinical trial of AK112 (PD-1/VEGF) in theUnited States
We obtained the IND approval for 德赢 from the FDA to begin a Phase Ib/II clinical trial in the United States
The Company was incorporated in the Cayman
Islands as an exempted company with limited liability
We initiated a Phase I clinical trial of ebronucimab (AK102) (PCSK9) in China
We obtained the IND approval for penpulimab (官网) with respect to cervical cancer and solid tumors from the FDA in the United States
We initiated a Phase I clinical trial for AK101 (IL-12/IL-23) in China
We initiated a Phase I clinical trial for penpulimab (官网) (PD-1) in Australia
We initiated a Phase I clinical trial (with chemotherapy) for 德赢 (PD-1/CTLA-4) for the treatment of solid tumors in Australia
We out-licensed AK107 (CTLA-4) to Merck (code name in Merck is MK1308)
We initiated the development of innovative ACE Platform and “TETRABODY” technology
Akeso Biopharma (中山德赢vwinvwin醫藥有限公司), our principal operating entity, was established in Zhongshan, China